Procept Biorobotics Corp PRCT.OQ PRCT.O is expected to show a rise in quarterly revenue when it reports results on November 4 for the period ending September 30 2025
The San Jose California-based company is expected to report a 38.7% increase in revenue to $80.943 million from $58.37 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.
LSEG's mean analyst estimate for Procept Biorobotics Corp is for a loss of 41 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Procept Biorobotics Corp is $62.00, about 44.5% above its last closing price of $34.38
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.40 | -0.41 | -0.35 | Beat | 15.6 |
Mar. 31 2025 | -0.49 | -0.49 | -0.45 | Beat | 8.2 |
Dec. 31 2024 | -0.33 | -0.33 | -0.35 | Missed | -6.8 |
Sep. 30 2024 | -0.48 | -0.49 | -0.40 | Beat | 18.1 |
Jun. 30 2024 | -0.52 | -0.52 | -0.50 | Beat | 4.3 |
Mar. 31 2024 | -0.55 | -0.56 | -0.51 | Beat | 8.2 |
Dec. 31 2023 | -0.44 | -0.44 | -0.54 | Missed | -23 |
Sep. 30 2023 | -0.51 | -0.51 | -0.51 | Met | 0.9 |
This summary was machine generated November 1 at 00:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)